Cardinal Health at-Home Solutions opens Texas distribution center; announces plans for new California site
CAH(NYSE:CAH) DUBLIN, Ohio, Sept. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced the opening of its newest distribution center in Fort Worth, Texas – a facility solely dedicated to the at-Home Solutions business, a leading medical supplies provider that serves more than 6 million people...
Cardinal Health Board of Directors Approves Quarterly Dividend
CAHDUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the...
Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance
CAHFourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expiration Fourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00 Fourth quarter non-GAAP operating earnings...
Cardinal Health announces the addition of Solaris Health, the country's leading urology MSO, to The Specialty Alliance
CAHAdds over 750 providers to Cardinal Health's multi-specialty MSO platform, The Specialty Alliance Joins with recent urology acquisitions to bolster The Specialty Alliance's leadership in the urology therapeutic area Cardinal Health MSO platforms reach ~3,000 providers in 32 states upon...
Evercore ISI Group Maintains Outperform on Cardinal Health, Raises Price Target to $180
CAHCardinal Health Expecting At Least $10B In Total Adjusted Free Cash Flow Over Next 3-Years; Raising Baseline Share Repurchase Plans To At Least $750M Per Year
CAHCardinal Health Raises FY25 Non-GAAP Diluted EPS Guidance To $8.15 - $8.20
CAHCardinal Health Provides Preliminary FY26 Guidance With Non-GAAP EPS Of $9.10-$9.30, Adj. FCF Of $2.75B-$3.25B, Capital Expenditures ~$600M, Sees Segment Revenue Growth Across Key Divisions; Updates Long-Term Targets Through 2028 Including 12% - 14% EPS C
CAHCardinal Health Analyst Flags Fading Scale Gap, Sees Rising Edge in Specialty Growth
CAHBofA's Lutz raised Cardinal Health's target to $170, citing specialty growth momentum and a shrinking scale gap as key upside drivers.
B of A Securities Maintains Buy on Cardinal Health, Raises Price Target to $170
CAHCitius Pharma's Subsidiary Citius Oncology Enters Into Distribution Services Agreement With Cardinal Health; Deal Supports Upcoming Launch Of LYMPHIR For Treatment Of Cutaneous T-Cell Lymphoma
CAHCardinal Health Announced The U.S. Launch Of Its Multi-parameter, Single-patient Use Monitoring Cable And Lead Wire System That Enables The Continuous Monitoring Of Cardiac Activity, Blood Oxygen Level And Temperature With One Point Of Connection
CAHWells Fargo Upgrades Cardinal Health to Overweight, Raises Price Target to $179
CAHWhat's Driving the Market Sentiment Around Cardinal Health?
CAH'Trump To Sign Order To Cut Some U.S. Drug Prices To Match Those Abroad' - CNBC
CAHMorgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $166
CAHUBS Maintains Buy on Cardinal Health, Raises Price Target to $170
CAHBaird Maintains Outperform on Cardinal Health, Raises Price Target to $170
CAHCardinal Health Lifts FY25 EPS Outlook, Sees Growth Despite Tariff Risks
CAHCardinal Health raised FY25 EPS guidance after Q3 profit gains in key segments, while revenue slightly missed estimates amid contract expirations.
Cardinal Health Raises FY2025 Adj EPS Guidance from $7.85-$8.00 to $8.05-$8.15 vs $7.96 Est
CAHCardinal Health Q3 Adj. EPS $2.35 Beats $2.17 Estimate, Sales $54.88B Miss $55.35B Estimate
CAHUBS Maintains Buy on Cardinal Health, Raises Price Target to $160
CAHIs the Market Bullish or Bearish on Cardinal Health?
CAHB of A Securities Maintains Buy on Cardinal Health, Raises Price Target to $155
CAHTelix Pharmaceuticals Has Selected Cardinal Health As One Of Its Commercial Radiopharmaceutical Distributors To Supply Finished Unit Doses Of Gozellix, PSMA-PET Imaging Agent For Prostate Cancer In US
CAHMizuho Maintains Outperform on Cardinal Health, Raises Price Target to $150
CAH13F Shows Elliott Investment Management Cuts Share Stake In Southwest Airlines Co By 2.4% To 59.7M Shares, Dissolves Share Stake In Cardinal Health Inc, Cuts Share Stake In NRG Energy Inc By 50.4% To 4.8M Shares
CAHElliott Investment Management Dissolves Share Stake In Cardinal Health Inc
CAH(CAH) - Analyzing Cardinal Health's Short Interest
CAH(CAH) - Analyzing Cardinal Health's Short Interest
CAHCardinal Health Expects FY25 Adj EPS To Be Toward Higher End Of $7.75-$7.90 Vs $7.84 Est
CAHCitigroup Maintains Neutral on Cardinal Health, Raises Price Target to $129
CAHJim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower (UPDATED)
CAHJMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60.
Cardinal Health Announced The U.S. Launch Of Its Kendall SCD SmartFlow Compression System, The Next Generation Of The Kendall Compression Series Offering An Enhanced Clinician And Patient Experience
CAHPeering Into Cardinal Health's Recent Short Interest
CAHMorgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $127
CAHDeutsche Bank Maintains Hold on Cardinal Health, Raises Price Target to $124
CAHUBS Maintains Buy on Cardinal Health, Raises Price Target to $139
CAHMizuho Maintains Neutral on Cardinal Health, Raises Price Target to $120
CAHBarclays Maintains Overweight on Cardinal Health, Raises Price Target to $133
CAHCardinal Health Executive Says Company Will Actively Evaluate Additional Opportunities To Accelerate Growth In Specialty Therapeutic Areas; GLP-1 Drugs Are Continuing To Contribute To Revenue And Grow More So Than We Had Originally Expected
CAHCardinal Health Raises 2025 Profit Outlook Again, Helped By Strong Drug Distribution Business
CAHCardinal Health reported Q1 2025 EPS of $1.88, surpassing estimates. Pharmaceutical revenue declined but grew 16% excluding contract expirations. FY 2025 EPS guidance raised.
Cardinal Health Raises Its Fiscal Year 2025 Outlook For Adjusted EPS To $7.75-$7.90 From Prior Guidance Of $7.55-$7.70 Versus Consensus Of $7.63
CAHCardinal Health Q1 2025 Adj EPS $1.88 Beats $1.62 Estimate, Sales $52.28B Beat $50.90B Estimate
CAHS&P 500 Records Worst Session In Over A Month, Meta And Microsoft Tumble: Greed Index Moves To 'Fear' Zone
CAHEarnings Outlook For Cardinal Health
CAHUnitedHealth's OptumRx Unveils New Transparent Drug Pricing Initiative for 2024
CAHUnitedHealth's OptumRx will implement a new pricing model, OptumRx Clear Trend Guarantee, starting next year.
Here's How Much You Would Have Made Owning Cardinal Health Stock In The Last 5 Years
CAHCardinal Health Reaffirms Guidance Range Of $5.05-$5.40 For Fiscal Year 2023
CAHCardinal Health Announces Victor Crawford Will Step Down As CEO Of Pharmaceutical Segment; Debbie Weitzman, President Of Pharmaceutical Distribution, Named CEO Of Pharmaceutical Segment
CAH